After sequential declines in June, most of the markets that cannabis data analytics firm BDSA covers saw advances during July, a month with one extra day. Tough comparisons from a year ago, when sales surged during the pandemic, resulted in relatively weak annual growth in most markets, with some even declining. In this review, we will look at the markets one-by-one, beginning with the more mature Western markets and then concluding with the newer Eastern markets.
BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In July, growth ranged from -14% in Colorado to 27% in Arizona compared to a year ago.
Arizona transitioned to adult-use in late January, but this is the fourth month that BDSA has included adult-use sales. Total cannabis sales grew 27% to $119.8 million, with adult-use representing $55.5 million, up 2% from June. Medical cannabis sales fell 32% from a year ago to $64 million. Sequentially, overall growth increased 1.7%, with medical flat and adult-use increasing 4%. Growth was strong across all categories, but the highest growth by far was in pre-rolls, which gained 175%.
Compared to a year ago, sales fell 0.5% to $332.5 million, up 0.2% sequentially. Pre-rolls expanded 27% compared to a year ago, while flower declined 9% and concentrates slipped 2%. Ingestibles expanded by 9%.
The mature market of Colorado, which has shown vigorous growth over the past year, declined 14% compared to a year ago, increasing 6.6% from June to $195.6 million. Flower sales fell almost 30% from a year ago, while pre-rolls expanded 14%. Concentrates and ingestibles were little changed from year-ago levels.
With the full reopening of Las Vegas behind it, Nevada’s July sales were surprisingly weak, advancing just 2%